AbbVie Inc. (ABBV) Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a premier pharmaceutical company renowned for its extensive portfolio of innovative medications. Established in 2012, AbbVie specializes in the discovery, development, manufacturing, and marketing of treatments primarily focused on autoimmune diseases, various cancers, and specialized eye conditions. The company’s flagship product, Humira, has positioned AbbVie as a leader in treatment options for rheumatoid arthritis, psoriasis, migraines, and advanced Parkinson’s disease. Currently, the drug manufacturing industry within the healthcare sector presents robust investment opportunities, with AbbVie at the forefront, showcasing a strong total revenue of approximately $55 billion.
Stock Performance & Financial Overview
As of the latest trading session, AbbVie’s stock price is sitting at $193.47. Analysts project a high target price of $218.00, indicating a promising upside potential for investors. The current average of analysts’ price predictions is pegged at $197.33, while the median price reflects a slightly higher valuation at $200.00. The stock exhibits a solid financial foundation, underpinned by considerable revenue figures. With a total of 1,766,339,968 shares outstanding and minimal short interest of 0.011%, investor sentiment points to optimism regarding AbbVie’s future performance. The stock is currently trading above its fifty-day moving average of 188.83, further signaling upward momentum. Over the past year, AbbVie has shown resilience, bouncing back from a fifty-two week low of 135.85 to a recent high of 199.95, solidifying its potential for future growth.
Analyst Insights & Recommendations
Analysts maintain a bullish sentiment towards AbbVie’s stock, reflected in a consensus “buy” rating with a recommendation mean of 2.1, based on insights from 25 analysts. The projected price estimates range dramatically, with a target high of $218.00 and a target low of $170.00, suggesting considerable optimism surrounding AbbVie’s capacity to capitalize on future market opportunities. With a strong revenue base and positive growth trajectory, the company’s stock remains an attractive opportunity in the healthcare sector for investors looking for sustainable returns.
This concise report presents an informative snapshot of AbbVie Inc.’s stock, highlighting crucial aspects for potential investors and supporting SEO optimization through the inclusion of relevant keywords.
| Metric | Value |
|---|---|
| Market Cap | $341.7b |
| Total Debt | $70.9b |
| Total Cash | $13.2b |
| Shares Outstanding | 1.8b |
| Float Shares | 1.8b |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.